For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Fields sold 7,500 shares of ReposiTrak. The total transaction amounted to $162,059. During ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

The ABC has obtained a more detailed cost estimate for the proposed Macquarie Point stadium, including the initial and ...

Dividend stocks provide income, even amid market sell-offs, and can hedge against inflation in 2025. Learn about 3 top ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, ...

Broadcom’s AI revenue surged, but its valuation is inflated. Learn why AVGO stock shows limited upside and may be due for a ...

A leading independent economist tasked with reviewing Tasmania's proposal to build an AFL stadium on Hobart's waterfront finds the project is "already displaying the hallmarks of mismanagement" and is ...